innoVitro

innoVitro is a private German preclinical contract research organization focused on human cell-based assays for drug safety, toxicity, efficacy, and disease-model testing, with particular strength in cardiac applications. The company uses label-free, real-time analytics to measure contractility, viability, connectivity, and electrophysiology in human cell models, including iPSC-derived cardiomyocytes. Its core commercial offering is built around proprietary and integrated assay technologies such as FLEXcyte 96, CardioExcyte 96, and AtlaZ. innoVitro appears to operate primarily as a service and platform company rather than a therapeutic drug developer, serving pharmaceutical, biotech, nutrition, and academic customers in preclinical research. Its offerings include functional and morphological cardiac liability testing, electrophysiology, cell line characterization, and custom disease models such as human-based atrial fibrillation and dilated cardiomyopathy assays.